C3 signs Italian distributor
Friday, 11 June, 2004
Perth-based tissue engineering company Clinical Cell Culture (C3, ASX:CCE) has signed Rome-based Health Defence to distribute its CellSpray and ReCell products in Italy.
CellSpray, a suspension of cultured skin cells, is used to treat major burns and scars. ReCell, an autologous skin harvesting device, will be marketed primarily for plastic and cosmetic surgery.
CEO Troels Jordansen said that C3 currently had distribution agreements for its products in place in Ireland, the UK, Germany, Switzerland, Holland, Belgium Luxembourg and France.
In April C3 also signed distribution agreements with Equipmed to market CellSpray and ReCell in Australia, excluding Western Australia, and New Zealand
The company is currently negotiating with distributors in the USA, Japan, South Africa, India and Brazil. It expects to sell its products in approximately 20 countries worldwide. Jordansen said he was confident that agreements will be in place in time for the launch of ReCell in 2005.
Health Defence will begin distributing the product once they have gained European CE Mark approval, anticipated at the end of this year.
“ReCell will be the big distribution generator,” said CEO Troels Jordan. “We will be focusing on the global cosmetic markets.”
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
